90jili club registration
Boeing Plea-Deal Rejection Adds Culture-War Topic to Turnaround
House Speaker Mike Johnson is reportedly not in good graces with President-elect Donald Trump. Johnson needs Trump’s support to keep the gavel on January 3, the day House Republicans will have an option to renew or cancel his speakership. Johnson’s response was to pass a bill without a debt level extension that only kept the government open until March 14. Politico’s Rachael Bade reported : Amid the chaos in Washington, I was in Palm Beach talking to people close to the past and future president and called up other confidants afterward. This much became clear to me: Not only is Trump unhappy with the funding deal, he’s unhappy with Johnson, too. He’s unhappy that he didn’t get the debt ceiling hike he made clear he wanted. He felt blindsided by the initial deal Johnson struck with Democrats. And, in the end, he was unimpressed with the entire chaotic process, which left the incoming administration questioning whether Johnson is capable of managing an even thinner majority next year. ... And, as of this weekend, it’s an open question at Mar-a-Lago about whether Trump will lift a finger to help him. Trump is sitting back and watching the coverage, I’m told, mulling whether it’s worth it to defenestrate another speaker. House Speaker Mike Johnson’s best chance to keep the gavel is to allow House Democrats to vote for him, Sen. Mitt Romney (R-UT) told reporters Friday. Johnson can only lose one House Republican without a single Democrat vote. Up to 25 House Republicans are possibly voting against Johnson for Speaker, a senior House GOP staffer told Breitbart News’s Matt Boyle. If Democrats, along with some establishment Republicans, enable Johnson to retain the speakership, he would be in a power-sharing agreement with House Minority Leader Hakeem Jeffries; the Democrat leader would demand something of Johnson in return for Democrat votes. A power-sharing agreement in the House seems unpalatable for Trump, who won a landslide election to implement his agenda. Johnson’s speakership, according to Romney’s scenario, appears to be in an untenable position: Johnson either accepts Democrat votes to remain Speaker, dismissing Trump’s mandate and infuriating the Republican base, or forgoes standing for re-election. Wendell Husebo is a political reporter with Breitbart News and a former RNC War Room Analyst. He is the author of Politics of Slave Morality. Follow Wendell on “X” @WendellHusebø or on Truth Social @WendellHusebo.IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced it has entered into a joint venture with 6 Dimensions Capital (“6 Dimensions”) and its successor fund 120 Capital, and VFLO Medical (“VFLO”), a medical device platform incubated by 6 Dimensions and 120 Capital, to provide access to Inari’s innovative technology for patients with significant unmet needs in Greater China. “This joint venture allows many different types of patients and hospitals to access and benefit from Inari’s technologies across multiple segments of China’s complex healthcare delivery system,” said Drew Hykes, Chief Executive Officer of Inari. “We are excited to partner with 6 Dimensions and 120 Capital to introduce our products through VFLO to the rapidly expanding interventional market in Greater China." “Inari is the leader in mechanical thrombectomy and our strategic partnership is significant and game-changing for the current standard of care in China,” said Rebecca Zhu, Managing Partner of 6 Dimensions Capital, and also Director of VFLO Medical. “We share Inari’s unwavering commitment to developing innovative technologies for underserved patients and believe we can make a meaningful difference in the lives of those suffering from venous and other vascular diseases in China.” The joint venture will allow Inari to commercialize its devices through VFLO’s established infrastructure, local relationships, and deep commercial expertise in Greater China. VFLO will also have the right to use Inari’s technology to manufacture products for domestic sale in Greater China. VFLO’s expertise and commitment to patients are complementary to Inari's global strengths in the development, manufacture, and sale of venous thrombectomy and other products. About Inari Medical, Inc. Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and four other targeted disease states. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn , X (Twitter) , and Instagram . About 6 Dimensions Capital and 120 Capital 120 Capital is a successor fund of 6 Dimensions Capital and is a US-domiciled leading global healthcare investment firm with offices in Boston, San Francisco, Hong Kong, and Shanghai. The firm is dedicated to supporting healthcare companies with operations in the US, Europe, China, Israel, and other regions. For more information, visit www.120capital.com . About VFLO Medical VFLO is a medical device company based in China that was established in 2021 by 6 Dimensions and 120 Capital, and a team of prominent and experienced industry professionals to create a leading medical device platform with a focus on making innovative vascular therapies available to Chinese patients. Forward-Looking Statements Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, and actual outcomes and results could differ materially due to a number of factors, including, among other things: the ability of the strategic venture to obtain regulatory approvals in China; the ability of VFLO to develop, manufacture, and commercialize venous thromboembolism and other products in China; the potential for and ability to receive any payments from VFLO; and the potential clinical benefits of Inari’s technologies in China. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the period ended December 31, 2023, and in Inari’s other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari. Investor Contact: Neil Bhalodkar IR@inarimedical.com
Israeli expert seeks new crime against humanity for waging violence against families
PARIS :Leaders Paris St Germain beat Toulouse 3-0 in Ligue 1 on Friday as the Parisians remained unbeaten in their domestic campaign following goals by Joao Neves, Lucas Beraldo and Vitinha. Neves put the hosts in front in the 35th minute with a volley from the edge of the area, before Beraldo doubled the lead with first touch late in the second half and substitute Vitinha sealed the win in stoppage time. PSG top the French top flight with 32 points, six ahead of second-placed AS Monaco who beat Brest 3-2 earlier on Friday. With their fifth consecutive win, PSG are one of the three teams among the European top five leagues that remain undefeated this season alongside Bundesliga leaders Bayern Munich and Juventus, currently sixth in Serie A. PSG, who travel to Bayern in the Champions League on Tuesday, started off cautiously against Toulouse, who handed the Parisians their only defeat in their previous 40 Ligue 1 games. League's top scorer Bradley Barcola was denied a good opportunity by Toulouse goalkeeper Guillaume Restes, an attempt that came one minute before Neves opened the scoring, netting a neat weighted pass from Achraf Hakimi low inside the left post. Hakimi had a chance of his own from a distance as PSG continued to dominate the possession after the restart, but Restes parried his shot above the bar. Warren Zaire-Emery then thought he doubled the lead for the hosts in the 54th minute, a goal that was ruled out for offside after a lengthy VAR review. Toulouse struggled to capitalise on the few chances that came their way, with substitute Shavy Babicka firing over the bar from close range minutes after entering the pitch. Beraldo, however, added a second in the 84th minute, scoring from around the penalty spot for his first goal of the season after he landed a rebound, before Vitinha netted a precise cross from fellow substitute Randal Kolo Muani to seal the points. Following their 1-0 win over Lens on Nov. 2, PSG have now kept two consecutive clean sheets at home in Ligue 1 for the first time in a year. They next host Nantes on Nov. 30. Toulouse, who are 10th on 15 points, welcome Auxerre on Dec. 1.
- Previous: 90jili club app
- Next: 90jili code